Clinical Application of Liquid Biopsy in Colorectal Cancer: Detection, Prediction, and Treatment Monitoring

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2024 Jul 16

PMID 39014366

Authors

Xiang-Yuan Tao

Qian-Qian Li

Yong Zeng

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is one of the most prevalent malignancies affecting the gastrointestinal tract and is ranked third among cancers with the highest incidence and second-highest mortality rate worldwide. CRC exhibits a slow progression providing a wide treatment window. The currently employed CRC screening methods have shown great potential to prevent CRC and reduce CRC-related morbidity and mortality. The diagnosis of CRC is achieved by colonoscopy and tissue biopsy, with studies showing that liquid biopsy is more effective in detecting and diagnosing early CRC patients. Increasing number of studies have shown that the tumor components shed into circulating blood can be detected in liquid form, and can be applied in the clinical management of CRC. Analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), or tumor-associated platelets (TEPs) in the blood can be used for early screening and diagnosis of CRC, aid tumor staging, treatment response monitoring, and prediction of CRC recurrence and metastasis in a minimally invasive manner. This chapter provides an updated review of CTCs, ctDNA, and TEPs as novel biomarkers for CRC, highlighting their strengths and limitations.

Citing Articles

Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review.

Ciappina G, Toscano E, Ottaiano A, Capuozzo M, Consolo P, Maiorana E Int J Mol Sci. 2025; 26(5).

PMID: 40076838 PMC: 11900077. DOI: 10.3390/ijms26052216.

5-Hydroxymethylcytosine modifications in circulating cell-free DNA: frontiers of cancer detection, monitoring, and prognostic evaluation.

Song D, Zhang Z, Zheng J, Zhang W, Cai J Biomark Res. 2025; 13(1):39.

PMID: 40055844 PMC: 11887266. DOI: 10.1186/s40364-025-00751-9.

Bibliometric analysis of global research trends and prospects on circulating tumor DNA in colorectal cancer.

Pang J, Bai P, Zhang Y, Wang L Front Oncol. 2024; 14:1428942.

PMID: 39619435 PMC: 11604578. DOI: 10.3389/fonc.2024.1428942.

Mapping the Future: A Comprehensive Bibliometric Analysis of Circulating Tumor DNA in Colorectal Cancer.

Wang C J Multidiscip Healthc. 2024; 17:5473-5486.

PMID: 39600714 PMC: 11590644. DOI: 10.2147/JMDH.S493863.

Liquid Biopsy in the Clinical Management of Cancers.

Ho H, Chung K, Kan C, Wong S Int J Mol Sci. 2024; 25(16).

PMID: 39201281 PMC: 11354853. DOI: 10.3390/ijms25168594.

References

Chen Y, Wang Z, Zhao G, Sun C, Ma Y, Zhang L . Performance of a Novel Blood-Based Early Colorectal Cancer Screening Assay in Remaining Serum after the Blood Biochemical Test. Dis Markers. 2019; 2019:5232780. PMC: 6476029. DOI: 10.1155/2019/5232780. View

Gao Y, Liu C, Li H, Xiong X, Li G, In t Veld S . Platelet RNA enables accurate detection of ovarian cancer: an intercontinental, biomarker identification study. Protein Cell. 2023; 14(6):579-590. PMC: 10246718. DOI: 10.1093/procel/pwac056. View

Shaukat A, Levin T . Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol. 2022; 19(8):521-531. PMC: 9063618. DOI: 10.1038/s41575-022-00612-y. View

Best M, Sol N, In t Veld S, Vancura A, Muller M, Niemeijer A . Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell. 2017; 32(2):238-252.e9. PMC: 6381325. DOI: 10.1016/j.ccell.2017.07.004. View

Wang F, Huang Y, Wu H, Wang Z, Jin Y, Yao Y . Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2021; 71(7):1340-1349. PMC: 9185813. DOI: 10.1136/gutjnl-2021-324852. View

Ye B, Li F, Chen M, Weng Y, Qi C, Xie Y . A panel of platelet-associated circulating long non-coding RNAs as potential biomarkers for colorectal cancer. Genomics. 2021; 114(1):31-37. DOI: 10.1016/j.ygeno.2021.11.026. View

Baek D, Kim G, Song G, Han I, Park E, Kim H . Clinical Potential of Circulating Tumor Cells in Colorectal Cancer: A Prospective Study. Clin Transl Gastroenterol. 2019; 10(7):e00055. PMC: 6708664. DOI: 10.14309/ctg.0000000000000055. View

Canellas-Socias A, Cortina C, Hernando-Momblona X, Palomo-Ponce S, Mulholland E, Turon G . Metastatic recurrence in colorectal cancer arises from residual EMP1 cells. Nature. 2022; 611(7936):603-613. PMC: 7616986. DOI: 10.1038/s41586-022-05402-9. View

Lecomte T, Berger A, Zinzindohoue F, Micard S, Landi B, Blons H . Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer. 2002; 100(5):542-8. DOI: 10.1002/ijc.10526. View

10.

Xu F, Yu S, Han J, Zong M, Tan Q, Zeng X . Detection of Circulating Tumor DNA Methylation in Diagnosis of Colorectal Cancer. Clin Transl Gastroenterol. 2021; 12(8):e00386. PMC: 8367071. DOI: 10.14309/ctg.0000000000000386. View

11.

Levin T, Corley D, Jensen C, Schottinger J, Quinn V, Zauber A . Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. Gastroenterology. 2018; 155(5):1383-1391.e5. PMC: 6240353. DOI: 10.1053/j.gastro.2018.07.017. View

12.

Worm Orntoft M . Review of Blood-Based Colorectal Cancer Screening: How Far Are Circulating Cell-Free DNA Methylation Markers From Clinical Implementation?. Clin Colorectal Cancer. 2018; 17(2):e415-e433. DOI: 10.1016/j.clcc.2018.02.012. View

13.

Barnell E, Wurtzler E, La Rocca J, Fitzgerald T, Petrone J, Hao Y . Multitarget Stool RNA Test for Colorectal Cancer Screening. JAMA. 2023; 330(18):1760-1768. PMC: 10594178. DOI: 10.1001/jama.2023.22231. View

14.

Sun G, Meng J, Duan H, Zhang D, Tang Y . Diagnostic Assessment of septin9 DNA Methylation for Colorectal Cancer Using Blood Detection: A Meta-Analysis. Pathol Oncol Res. 2018; 25(4):1525-1534. DOI: 10.1007/s12253-018-0559-5. View

15.

Burciaga-Hernandez L, Cueto-Villalobos C, Ortega-Pinon N, Gonzalez-Curiel I, Godina-Gonzalez S, Mendez-Frausto G . Gene Expression Behavior of a Set of Genes in Platelet and Tissue Samples from Patients with Breast Cancer. Int J Mol Sci. 2023; 24(9). PMC: 10179257. DOI: 10.3390/ijms24098348. View

16.

Pittella-Silva F, Chin Y, Chan H, Nagayama S, Miyauchi E, Low S . Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?. Clin Chem. 2020; 66(7):946-957. DOI: 10.1093/clinchem/hvaa103. View

17.

Peterson J, Zurakowski D, Italiano Jr J, Michel L, Connors S, Oenick M . VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012; 15(2):265-73. DOI: 10.1007/s10456-012-9259-z. View

18.

Kim H, Choi C, Lee Y, Kim T, Lee J, Bae D . Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings. Taiwan J Obstet Gynecol. 2014; 53(3):343-7. DOI: 10.1016/j.tjog.2013.10.041. View

19.

Zhang Q, Rong Y, Yi K, Huang L, Chen M, Wang F . Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications. Theranostics. 2020; 10(26):12060-12071. PMC: 7667686. DOI: 10.7150/thno.48918. View

20.

Gay L, Felding-Habermann B . Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011; 11(2):123-34. PMC: 6894505. DOI: 10.1038/nrc3004. View